COVID-19: Building on the HIV response to introduce innovation in a pandemic

Lucy Stackpool-Moore is the former Director, HIV Programmes and Advocacy at the IAS in Switzerland. She is currently a Senior Advisor (consultative role) at the IAS. Her professional experience is founded in multi-sectoral responses to HIV and public health, “rights-from-below” approaches to human rights and participatory approaches that amplify diverse voices and enable community development. As a researcher and advocate, her work has focused on documenting and transforming stigma and discrimination in relation to HIV. Stackpool-Moore is a Visiting Fellow with the Law Schools at Birkbeck University of London, UK, and University of Melbourne, Australia, and supervises MSc projects with the Global Health Policy programme at the London School of Hygiene & Tropical Medicine. She has worked for a variety of international non-governmental organizations and campaigns and has provided technical support to various UN agencies, donors and civil society organizations in Asia and the Pacific, East and southern Africa and the Middle East and North Africa.

Sharon Lewin is an infectious diseases physician and basic scientist and has worked in HIV-related clinical medicine and research for over 25 years. She is Director of the Peter Doherty Institute for Infection and Immunity, a joint venture of the University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia. The Doherty Institute has over 850 staff working on infection and immunity through research, education and public health, and has a significant focus on virology, including HIV. She is an active clinician, working at the Alfred Hospital and Royal Melbourne Hospital, and a Melbourne Laureate Professor of Medicine at the University of Melbourne.

Sharon is internationally recognized for her expertise in HIV cure, HIV-hepatitis B virus (HBV) co-infection and SARS-CoV-2 infection. She leads a large group focused on basic and translational science and early-phase clinical trials for cure interventions and is actively developing antiviral strategies for novel RNA viruses using RNA editing. She collaborates widely, including a long-standing partnership with researchers in Thailand on living with both HIV and HBV, and is a co-PI on DARE, a large NIH-funded network of researchers working on HIV cure. She has published over 350 manuscripts, predominately related to HIV cure and understanding HIV disease and related conditions, including HBV, cryptococcal infection and cytomegalovirus. She is also active in COVID-19 research. The Doherty Institute was the first to isolate SARS-CoV-2 and share the virus globally.

She has been an IAS Member since 2007, when she was Deputy Chair of IAS 2007 in Sydney. As Local Co-Chair for AIDS 2014 in Melbourne, she leveraged significant in-kind and financial support from the Australian and Victorian Governments and the city of Melbourne. With her Australian colleagues, she led several advocacy programmes in relation to AIDS 2014, which resulted in every Australian state health minister signing a declaration to see the end of new HIV acquisitions in Australia by 2020. She is the key opinion leader for Melbourne as a UNAIDS Fast-Track City. She chairs the Advisory Board for the IAS Towards an HIV Cure initiative, and with Steve Deeks, co-chairs the annual IAS workshop on HIV cure and the HIV cure research academies.

Her work has been recognized with the following major awards:

Melburnian of the Year (2014), awarded to a role model who has made an outstanding contribution to the city in their field, as well as a significant contribution to the community

Peter Wills Medal (2015), awarded by Research Australia to an Australian who has made an outstanding contribution to building Australia’s reputation in health and medical research, and fostering collaboration for better health

Officer of the Order of Australia (2019) for distinguished service of a high degree to Australia in the field of infectious diseases and HIV and AIDS

Committee for Melbourne Achiever Award (2020) for making a major contribution to the city of Melbourne, which will transform its future

The National Health and Medical Research Council (NHMRC) (2020) of Australia Outstanding Contribution Award

She was a member of the council of the NHMRC, the peak funding body for medical research in Australia, and chaired its Health Translation Advisory Committee (2016-2021). She is a member of the Governing Board of the International Coalition for the Elimination of Hepatitis B virus (ICE-HBV) and the executive of the Global Virology Network. She was previously President of the Australian Society for HIV Medicine. She is a member of the Scientific Advisory Board of the Vaccine Research Centre at the NIH and President of the Scientific Advisory Board of the newly formed ANRS/MIE (Maladies Infectiouses Emergentes) in France.

James F Rooney joined Gilead Sciences in 1996 as Vice President of Clinical Research and, in 2004, became Vice President of Medical Affairs. From 2004 to 2006, he was also Vice President of Drug Safety and Public Health. James Rooney has been instrumental in the clinical development of the company's antiviral therapies, including for HIV, hepatitis B and C, influenza and COVID-19. Dr Rooney also leads many of the company's clinical research activities in low- and middle-income countries.

Previously, Dr Rooney worked as a global project leader in HIV at Burroughs Wellcome and Glaxo Wellcome. He received his undergraduate degree at Harvard University in Cambridge, Massachusetts, his medical degree and residency training in internal medicine at the University of Maryland Hospital in Baltimore, Maryland, and his training in infectious diseases at the Laboratory of Clinical Investigation, National Institutes of Health, Bethesda, Maryland. Dr Rooney is board certified in Internal Medicine and Infectious Diseases and is a Fellow of the Infectious Diseases Society of America.

Maureen Luba is a Malawian global health practitioner currently serving as Program Manager at Cooper Smith. She helps lead the organization’s efforts around strengthening health information and data systems in Malawi to improve health outcomes, working closely with the government and other stakeholders. She is a passionate and staunch advocate for women’s health and has more than 13 years of experience working on HIV, TB and sexual and reproductive health and rights advocacy.

Maureen serves on several national, regional and global platforms, where she continues to advocate and fight for access to quality health services for underprivileged communities. This includes serving as a board member for the International Partnership for Microbicides. She is currently pursuing a Master of Medical Sciences in Global Health Delivery at Harvard Medical School.